Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by LtGhoston Mar 05, 2020 1:27pm

103 Views

Post# 30771325

RE:RE:RE:The NEXT GW PHARMA ? ? ? ?

If they plan to acquire an unrelated company, I am good with that. With the CEO of stero is the former COO of Kalytera and owner of talents and shared the same CSO and CMO, it raised my concern.

We are all waiting for the news before Mar 15. But with this NR, I am concerned will we get the news we all wanted. Cuz, Talent can extend the payment if they wanted, as they seems all run by the same group of ppls.

Bullboard Posts

Canadian artificial intelligence ETFs